- Home
- MRK vs NVO Comparison
MRK vs NVO Comparison
Compare MRK & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRK
- NVO
- Stock Information
- Founded
- MRK 2000
- NVO 1923
- Country
- MRK United States
- NVO Denmark
- Employees
- MRK N/A
- NVO N/A
- Industry
- MRK Biotechnology: Pharmaceutical Preparations
- NVO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MRK Health Care
- NVO Health Care
- Exchange
- MRK Nasdaq
- NVO Nasdaq
- Market Cap
- MRK 218.8B
- NVO 243.4B
- IPO Year
- MRK N/A
- NVO N/A
- Fundamental
- Price
- MRK $87.40
- NVO $53.00
- Analyst Decision
- MRK Buy
- NVO Buy
- Analyst Count
- MRK 15
- NVO 9
- Target Price
- MRK $105.14
- NVO $80.40
- AVG Volume (30 Days)
- MRK 12.0M
- NVO 12.2M
- Earning Date
- MRK 10-30-2025
- NVO 11-05-2025
- Dividend Yield
- MRK 3.70%
- NVO 2.32%
- EPS Growth
- MRK 20.41
- NVO 24.25
- EPS
- MRK 6.49
- NVO 3.93
- Revenue
- MRK $63,616,000,000.00
- NVO $49,108,936,497.00
- Revenue This Year
- MRK $1.76
- NVO $9.58
- Revenue Next Year
- MRK $5.11
- NVO $7.39
- P/E Ratio
- MRK $13.49
- NVO $13.48
- Revenue Growth
- MRK 1.82
- NVO 20.91
- 52 Week Low
- MRK $73.31
- NVO $45.05
- 52 Week High
- MRK $106.62
- NVO $115.26
- Technical
- Relative Strength Index (RSI)
- MRK 58.17
- NVO 36.63
- Support Level
- MRK $86.91
- NVO $52.38
- Resistance Level
- MRK $88.79
- NVO $56.23
- Average True Range (ATR)
- MRK 1.54
- NVO 1.03
- MACD
- MRK 0.11
- NVO -0.56
- Stochastic Oscillator
- MRK 73.34
- NVO 7.94
About MRK Merck & Company Inc. (new)
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
About NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.